MODERN PERSPECTIVES ON CUTANEOUS T-CELL LYMPHOMA: UPDATE ON CLASSIFICATION, AND EVOLVING THERAPEUTIC STRATEGIES

Ariel Ekaputra (Departemen Kulit dan Kelamin, Rumah Sakit Umum Daerah Wangaya, Denpasar, Bali)
Putu Dyah Ayu Saraswati (Departemen Kulit dan Kelamin, Rumah Sakit Umum Daerah Wangaya, Denpasar, Bali)
Edward Edwin (Departemen Kulit dan Kelamin, Rumah Sakit Umum Daerah Wangaya, Denpasar, Bali)
Dana Parama Julius (Departemen Kulit dan Kelamin, Rumah Sakit Umum Daerah Wangaya, Denpasar, Bali)

SEHAT : JURNAL KESEHATAN TERPADU
Vol. 4 No. 4 (2025)

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of primary cutaneous non-Hodgkin lymphomas, predominantly represented by mycosis fungoides (MF) and Sézary syndrome (SS), with updated WHO-EORTC and WHO 5th edition classifications incorporating molecular and immunophenotypic criteria that better distinguish indolent subtypes—such as MF, SS, primary cutaneous CD30+ lymphoproliferative disorders, and primary cutaneous acral CD8+ T-cell lymphoma from aggressive variants including primary cutaneous γδ T-cell lymphoma and extranodal NK/T-cell lymphoma. Diagnosis requires integrated clinicopathologic assessment supported by immunophenotyping and clonality studies, while the ISCL/EORTC TNMB staging remains fundamental for prognostication and guides stage-based management, ranging from skin-directed therapy in early-stage to systemic, immunomodulatory, biologic, and targeted approaches in advanced disease. Advances in molecular profiling and biomarker development are expected to further refine risk stratification and support personalized therapy.